Terkko Navigator / Leukemia

Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma

AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome

Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study

Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study

Correction: PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways

A comprehensive review of the impact of obesity on plasma cell disorders

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells

Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma

Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis

Normal life expectancy for polycythemia vera (PV) patients is possible

HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions

Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML

HGNC nomenclature for fusion genes

Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis

Chromatin remodeling subunit BRM and valine regulate hematopoietic stem/progenitor cell function and self-renewal via intrinsic and extrinsic effects

Stress hematopoiesis induces a proliferative advantage in TET2 deficiency

Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression

Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma

Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?

The clinical utility of polygenic risk scores for chronic lymphocytic leukemia

Spred1 deficit promotes treatment resistance and transformation of chronic phase CML

Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients

Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia

Circulating cytokines present in multiple myeloma patients inhibit the osteoblastic differentiation of adipose stem cells

Correction: Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders

Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas

Gene therapy in a murine model of chronic eosinophilic leukemia-not otherwise specified (CEL-NOS)

DNA-TG and risk of sinusoidal obstruction syndrome in childhood acute lymphoblastic leukemia

Valeriy Grigorievich Savchenko: pioneering Russian haematologist 8 January 1952–25 July 2021

Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia

Publisher Correction: The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

Full-length HLA sequencing in adult T cell leukemia–lymphoma uncovers multiple gene alterations

Oncostatin M regulates hematopoietic stem cell (HSC) niches in the bone marrow to restrict HSC mobilization

RBC distribution width predicts thrombosis risk in polycythemia vera

The impact of specific cytokine directed treatment on severe COVID-19

Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis

Correction: Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq

Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

Correction: Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Pa

Correction to: Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome

The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia

PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression

Lysosomes in acute myeloid leukemia: potential therapeutic targets?

TET3 promotes AML growth and epigenetically regulates glucose metabolism and leukemic stem cell associated pathways

Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma

Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients

Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease

Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group